Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.

Autor: Bednarek R; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland. radoslaw.bednarek@umed.lodz.pl., Selmi A; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland., Wojkowska D; Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland., Karolczak K; Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland., Popielarski M; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland., Stasiak M; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland., Salifu MO; Department of Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY, USA., Babinska A; Department of Medicine, State University of New York, Downstate Medical Center, Brooklyn, NY, USA., Swiatkowska M; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Jan; Vol. 179 (2), pp. 325-335. Date of Electronic Publication: 2019 Oct 24.
DOI: 10.1007/s10549-019-05471-x
Abstrakt: Purpose: To examine the involvement of the F11R/JAM-A protein in breast cancer metastasis, we utilized the F11R/JAM-A antagonistic peptide 4D (P4D) in experiments of transendothelial migration (TEM) of breast cancer cells.
Methods: Experiments were conducted in the mouse 4T1 breast cancer model utilizing the human mammary epithelial cell and endothelial cell lines. The levels of soluble F11R/JAM-A (sJAM-A) in the murine plasmas were measured by ELISA. Levels of F11R/JAM-A mRNA and protein in cell lines were assessed by qRT-PCR and Western blot, respectively. Cell surface expression of F11R/JAM-A was demonstrated by flow cytometry. Functional tests included the TEM of breast cancer cells and adhesion of breast cancer cells to the endothelium. The endothelial permeability was studied by fluorescent tracer assay and by the Real-Time Cell Analysis (RTCA).
Results: The tumor inducers Tβ4 and TGF-β1 reduced the levels of sJAM-A in murine plasma, and reduced the F11R/JAM-A protein levels in the human microvascular endothelial cell line HMEC-1. The adhesion and TEM measured between breast cancer cells and inflamed or Tβ4-treated endothelium were inhibited by P4D. The presence of P4D did not destabilize the pre-existing tight junctions in the endothelial monolayer. The barrier-protecting effect of P4D was stronger than that of forskolin, when a booster dose of P4D was applied to the inflamed endothelium.
Conclusions: F11R/JAM-A protein can be considered as a novel target in the treatment of breast cancer metastasis. In vivo and clinical studies are needed to further investigate the effectiveness of F11R/JAM-A-derived peptide as a possible anti-metastatic drug.
Databáze: MEDLINE
Externí odkaz: